Bone Loss Five Years After Gastric Bypass: Standard Dosing or Malabsorption-Adjusted Repletion
A single patient whose weight-loss surgery is a real success story that came with a quieter cost. The disagreement is whether the usual osteoporosis playbook even works once the gut it depends on has been surgically rerouted.
Perpetua M., a 52-year-old woman, underwent Roux-en-Y gastric bypass five years ago after decades of struggling with severe obesity, and describes the surgery as the single best medical decision she has made: substantial weight loss maintained, type 2 diabetes resolved, and hiking taken up with a local club she would never have joined before. A DXA ordered as part of her long-term post-bariatric surveillance found osteoporosis she did not have before surgery — a femoral neck T-score of −2.5 — alongside a corrected calcium of 8.6 and a 25-OH vitamin D of 19, both low despite what she describes as consistent daily supplementation with an over-the-counter calcium carbonate tablet, 500 mg twice a day.
Roux-en-Y bypass surgically excludes the duodenum and proximal jejunum, where most dietary and supplemental calcium is normally absorbed, and reroutes food past them. That anatomic change is permanent rather than something that improves with time, and it means the supplement she has taken faithfully every day may never have been well absorbed — not a compliance problem but an anatomy problem the specific formulation does not account for. Calcium carbonate compounds it, because it requires gastric acid to dissolve before absorption can even be attempted, and her remnant pouch does not reliably supply that. The AACE/TOS/ASMBS perioperative nutritional guidelines, Mechanick and colleagues, name calcium citrate rather than carbonate as the preferred formulation after malabsorptive procedures for exactly this reason. Her PTH of 88 is what settles which explanation is operating. An elevated parathyroid hormone alongside a corrected calcium of 8.6 and a 25-OH vitamin D of 19 is the signature of a gland responding appropriately to calcium that never arrived — secondary hyperparathyroidism driven by malabsorption. A patient who simply was not taking her supplement would show the same low calcium; she would not have spent five years driving her parathyroid glands with a tablet she was faithfully swallowing and never absorbing.
Why the supplement she's been taking hasn't been working
My instinct is to titrate her current calcium carbonate dose upward and see if higher, more frequent oral dosing gets her numbers into range — many post-bariatric patients I've managed achieve adequate repletion that way without needing to change formulation right away.
I don't think that's likely to work for her specifically, given her anatomy. Roux-en-Y bypass excludes the duodenum and proximal jejunum — the primary calcium-absorption sites — and calcium carbonate specifically requires gastric acid to dissolve before it can be absorbed, an acid-dependent step her altered anatomy doesn't reliably provide. The AACE/TOS/ASMBS perioperative nutritional guidelines, Mechanick and colleagues, name calcium citrate rather than carbonate as the preferred formulation after malabsorptive procedures for exactly this reason.
Higher doses of a formulation that isn't being absorbed well in the first place is more likely to just pass through unabsorbed — calcium citrate, which doesn't require that acid-dependent dissolution step, is the more appropriate starting point, not something to escalate to later.
Worth extending that same logic to her bisphosphonate question, which is separate from calcium but driven by the identical anatomic problem. Oral bisphosphonates also require intact upper gastrointestinal absorption — the same segments her bypass excludes.
Given that, an IV bisphosphonate should be the default starting choice here, not something reached for only after an oral agent is tried and predictably underperforms — her anatomy already tells us what an oral agent is up against before we start.
Agreed: switch to calcium citrate, start IV zoledronic acid rather than an oral bisphosphonate, and increase her vitamin D3 dose, explicitly explaining to Perpetua that her prior regimen's underperformance reflected her surgical anatomy rather than any failure of her own consistent adherence.
Not fully settled: how frequently to recheck her labs during the transition to confirm the new formulations are actually being absorbed better — the primary care physician preferred the standard post-bariatric surveillance interval, the endocrinologist wanted an earlier check given how low her current numbers are, and the earlier interval was adopted for this round only.